Body mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies.
Cardiovascular diseases
Comorbidities
Multimorbidity
Obesity
Obesity-related cancers
Type 2 diabetes
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
received:
03
05
2023
accepted:
16
10
2023
medline:
24
11
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
epublish
Résumé
Whether cancer risk associated with a higher body mass index (BMI), a surrogate measure of adiposity, differs among adults with and without cardiovascular diseases (CVD) and/or type 2 diabetes (T2D) is unclear. The primary aim of this study was to evaluate separate and joint associations of BMI and CVD/T2D with the risk of cancer. This is an individual participant data meta-analysis of two prospective cohort studies, the UK Biobank (UKB) and the European Prospective Investigation into Cancer and nutrition (EPIC), with a total of 577,343 adults, free of cancer, T2D, and CVD at recruitment. We used Cox proportional hazard regressions to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between BMI and incidence of obesity-related cancer and in turn overall cancer with a multiplicative interaction between BMI and the two cardiometabolic diseases (CMD). HRs and 95% CIs for separate and joint associations for categories of overweight/obesity and CMD status were estimated, and additive interaction was quantified through relative excess risk due to interaction (RERI). In the meta-analysis of both cohorts, BMI (per ~ 5 kg/m Irrespective of CMD status, higher BMI increased the risk of obesity-related cancer among European adults. The additive interaction between obesity and CVD suggests that obesity prevention would translate into a greater cancer risk reduction among population groups with CVD than among the general population.
Sections du résumé
BACKGROUND
BACKGROUND
Whether cancer risk associated with a higher body mass index (BMI), a surrogate measure of adiposity, differs among adults with and without cardiovascular diseases (CVD) and/or type 2 diabetes (T2D) is unclear. The primary aim of this study was to evaluate separate and joint associations of BMI and CVD/T2D with the risk of cancer.
METHODS
METHODS
This is an individual participant data meta-analysis of two prospective cohort studies, the UK Biobank (UKB) and the European Prospective Investigation into Cancer and nutrition (EPIC), with a total of 577,343 adults, free of cancer, T2D, and CVD at recruitment. We used Cox proportional hazard regressions to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between BMI and incidence of obesity-related cancer and in turn overall cancer with a multiplicative interaction between BMI and the two cardiometabolic diseases (CMD). HRs and 95% CIs for separate and joint associations for categories of overweight/obesity and CMD status were estimated, and additive interaction was quantified through relative excess risk due to interaction (RERI).
RESULTS
RESULTS
In the meta-analysis of both cohorts, BMI (per ~ 5 kg/m
CONCLUSIONS
CONCLUSIONS
Irrespective of CMD status, higher BMI increased the risk of obesity-related cancer among European adults. The additive interaction between obesity and CVD suggests that obesity prevention would translate into a greater cancer risk reduction among population groups with CVD than among the general population.
Identifiants
pubmed: 37993940
doi: 10.1186/s12916-023-03114-z
pii: 10.1186/s12916-023-03114-z
pmc: PMC10666332
doi:
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
418Subventions
Organisme : World Cancer Research Fund
ID : IIG_2019_1978
Informations de copyright
© 2023. The Author(s).
Références
Circulation. 2018 Aug 14;138(7):678-691
pubmed: 29459363
Cancer Epidemiol. 2016 Apr;41:8-15
pubmed: 26775081
Front Oncol. 2021 Feb 02;10:615375
pubmed: 33604295
Public Health Nutr. 2002 Aug;5(4):561-5
pubmed: 12186665
Epidemiology. 1992 Sep;3(5):452-6
pubmed: 1391139
JACC CardioOncol. 2021 Mar;3(1):48-58
pubmed: 33870217
Diabetologia. 2011 Sep;54(9):2272-82
pubmed: 21717116
Sci Rep. 2021 Jan 28;11(1):2479
pubmed: 33510262
JAMA. 2010 Nov 24;304(20):2290-1
pubmed: 21098774
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Eur J Epidemiol. 2007;22(2):129-41
pubmed: 17295097
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Cardiovasc Diabetol. 2019 Jul 30;18(1):96
pubmed: 31362743
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Front Oncol. 2022 Sep 05;12:950971
pubmed: 36147909
BMJ. 2015 Jan 02;350:g7607
pubmed: 25555821
BMC Med. 2021 Jan 14;19(1):10
pubmed: 33441148
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Int J Epidemiol. 2007 Oct;36(5):1111-8
pubmed: 17726040
Diabetologia. 2018 Oct;61(10):2140-2154
pubmed: 30027404
Circulation. 2020 Aug 18;142(7):670-683
pubmed: 32475164
J Epidemiol Glob Health. 2020 Mar;10(1):107-111
pubmed: 32175717
J Gerontol B Psychol Sci Soc Sci. 2012 May;67(3):279-88
pubmed: 21983040
Public Health Nutr. 2002 Dec;5(6B):1147-62
pubmed: 12639224
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Nat Rev Cancer. 2015 Aug;15(8):484-98
pubmed: 26205341
Epidemiology. 2011 Sep;22(5):745
pubmed: 21811114
PLoS One. 2015 Jul 29;10(7):e0134321
pubmed: 26222906
Eur J Epidemiol. 2011 Nov;26(11):863-76
pubmed: 21938478
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Curr Drug Saf. 2013 Nov;8(5):296-332
pubmed: 24215312
PLoS One. 2013 Jul 30;8(7):e65174
pubmed: 23935815
Cancer Med. 2023 Oct;12(19):20188-20200
pubmed: 37766588
Lancet. 2017 Mar 4;389(10072):941-950
pubmed: 28271845
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Diabetologia. 2007 Jul;50(7):1365-74
pubmed: 17476474
BMC Med. 2020 Jan 10;18(1):5
pubmed: 31918762
Cancer Prev Res (Phila). 2014 Sep;7(9):867-85
pubmed: 24985407
Maturitas. 2010 Sep;67(1):60-6
pubmed: 20494530
Nat Med. 2020 Sep;26(9):1452-1458
pubmed: 32661390
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120